Scaling new heights in the fight against heart disease
Founded by leading cardiovascular scientists, our team has the tenacity to pursue our ultimate peak – changing the treatment paradigm for heart disease, and in doing so improving and extending the lives of millions of individuals and families fighting this debilitating disease.
We are a biotechnology company committed to a bold mission: to discover, design, develop and deliver curative therapies that address the underlying drivers of heart disease.
We are revolutionizing the treatment of heart disease through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine.
LATEST NEWS
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
Phase 1b Clinical Trial for TN-201 in MYBPC3-associated HCM Patients Expected to Begin Dosing in Third Quarter 2023; Data Anticipated in 2024 Data from First-in-Human Clinical Trial of TN-301 Anticipated in Second Half 2023 TN-401 IND Submission Planned in Second Half 2023 Cash Runway Extended
Read MoreTenaya Therapeutics Appoints Amy Burroughs to Board of Directors
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the
Read MoreTenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy
TN-401 is being developed for the treatment of genetic arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by mutations in the PKP2 gene Orphan Drug Designation for TN-401 is the first for a gene therapy treatment for ARVC Expect to submit TN-401 IND application to the FDA in 2023 SOUTH
Read MoreJOIN OUR TEAM
Are you ambitious, driven, energized by scientific innovation and committed to making a difference for patients suffering from heart disease? Do you value a culture grounded in science and collaboration? Our team combines deep biological insights, sophisticated drug development technologies and a boundless determination to change the future for the millions of people affected by heart disease.
